Lilly's Carroll: Let's Debate Pricing But Don't Lump Us With Turing
This article was originally published in Scrip
Executive Summary
At the recent BIO-Europe meeting, held in Munich, Germany, Eli Lilly & Co's senior vice president of corporate business development Darren Carroll, in an exclusive interview with Scrip, highlighted his expectations for 2016 and concerns for innovative pharmaceutical companies being tarred with the same brush as current businesses which are under the spotlight for unfounded soaring drug prices in the US.